John R Wunderlich

Title: John R. Wunderlich: Innovator in Cancer Immunotherapy

Introduction

John R. Wunderlich is a notable inventor based in Bethesda, MD (US), recognized for his contributions to the field of cancer immunotherapy. He holds 2 patents that focus on innovative methods to promote cancer regression in mammals. His work is pivotal in advancing treatment options for patients battling cancer.

Latest Patents

Wunderlich's latest patents include a method of immunotherapy utilizing in vitro-selected antigen-specific lymphocytes following non-myeloablative lymphodepleting chemotherapy. This method involves administering non-myeloablative lymphodepleting chemotherapy to a mammal, followed by the administration of autologous T-cells that have been isolated and selected for their ability to recognize cancer antigens. The T-cells are rapidly expanded in vitro and can be administered either concomitantly or subsequently with a T-cell growth factor that enhances their growth and activation. This innovative approach aims to promote the regression of cancer effectively.

Career Highlights

John R. Wunderlich is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution underscores his commitment to advancing medical research and developing effective cancer therapies.

Collaborations

Wunderlich collaborates with esteemed colleagues, including Mark E. Dudley and Steven A. Rosenberg. These partnerships enhance the research efforts and contribute to the development of groundbreaking cancer treatments.

Conclusion

John R. Wunderlich's innovative work in cancer immunotherapy exemplifies the potential of targeted treatments in the fight against cancer. His patents and collaborations reflect a dedication to improving patient outcomes through scientific advancement.